Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Veeral Sheth (ORCID: https://orcid.org/0000-0002-7467-9947)
- Usha Chakravarthy (ORCID: https://orcid.org/0000-0002-2606-3734)
- Arshad M. Khanani (ORCID: https://orcid.org/0000-0001-8928-5599)
- Katie F. Maass
- Shamika Gune (ORCID: https://orcid.org/0000-0001-9963-5652)
- Nancy M. Holekamp (ORCID: https://orcid.org/0000-0001-7850-8515)
- Steven Blotner
- Aleksandra Rachitskaya (ORCID: https://orcid.org/0000-0001-5545-9474)
- D. Heinrich
Institutions
- Roche (Switzerland) (CH)
- Queen's University Belfast (GB)
- Cleveland Clinic (US)
- University of Nevada, Reno (US)
- Pepose Vision Institute (US)
- Illinois Retina Associates (US)
- Sierra Eye Associates (US)
Publication Details
- Journal
- Ophthalmology Retina
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1016/j.oret.2024.10.015
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.08
Funders
- F. Hoffmann-La Roche